ATE387909T1 - Verfahren und zusammensetzungen zur behandlung von neoplastischen erkrankungen mittels chemotherapie und strahlungssensibilisatoren - Google Patents

Verfahren und zusammensetzungen zur behandlung von neoplastischen erkrankungen mittels chemotherapie und strahlungssensibilisatoren

Info

Publication number
ATE387909T1
ATE387909T1 AT01948255T AT01948255T ATE387909T1 AT E387909 T1 ATE387909 T1 AT E387909T1 AT 01948255 T AT01948255 T AT 01948255T AT 01948255 T AT01948255 T AT 01948255T AT E387909 T1 ATE387909 T1 AT E387909T1
Authority
AT
Austria
Prior art keywords
methods
kiaa0175
compositions
neoplastic diseases
chemotherapy
Prior art date
Application number
AT01948255T
Other languages
English (en)
Inventor
Bin Wu
Todd Seeley
Lewis Williams
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE387909T1 publication Critical patent/ATE387909T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01037—Protein kinase (2.7.1.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
AT01948255T 2000-05-31 2001-05-30 Verfahren und zusammensetzungen zur behandlung von neoplastischen erkrankungen mittels chemotherapie und strahlungssensibilisatoren ATE387909T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20843500P 2000-05-31 2000-05-31

Publications (1)

Publication Number Publication Date
ATE387909T1 true ATE387909T1 (de) 2008-03-15

Family

ID=22774595

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01948255T ATE387909T1 (de) 2000-05-31 2001-05-30 Verfahren und zusammensetzungen zur behandlung von neoplastischen erkrankungen mittels chemotherapie und strahlungssensibilisatoren

Country Status (10)

Country Link
US (2) US6974867B2 (de)
EP (1) EP1292289B1 (de)
JP (1) JP2003534786A (de)
AT (1) ATE387909T1 (de)
AU (1) AU2001269726A1 (de)
CA (1) CA2410516A1 (de)
DE (1) DE60133104T2 (de)
ES (1) ES2299493T3 (de)
PT (1) PT1292289E (de)
WO (1) WO2001091739A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004024063A2 (en) * 2002-09-11 2004-03-25 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7879545B2 (en) * 2003-11-05 2011-02-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. Identification of novel targets for radio sensitization using a genomic-based radiation sensitivity classifier
JP5028601B2 (ja) * 2004-08-10 2012-09-19 オンコセラピー・サイエンス株式会社 乳癌に関連する遺伝子およびポリペプチド
WO2006039582A2 (en) * 2004-09-30 2006-04-13 The Regents Of The University Of California Compositions and methods for diagnosing and treating brain cancer and identifying neural stem cells
US20090076734A1 (en) 2007-03-22 2009-03-19 Torres-Roca Javier F Gene Signature for the Prediction of Radiation Therapy Response
US20080234946A1 (en) * 2007-03-22 2008-09-25 University Of South Florida Predictive radiosensitivity network model
JP2010539890A (ja) * 2007-09-14 2010-12-24 ユニヴァーシティ オブ サウス フロリダ 放射線治療の応答を予測するための遺伝子シグネチャー
TWI466680B (zh) 2008-08-01 2015-01-01 Oncotherapy Science Inc Ｍｅｌｋ抗原決定位胜肽及含此胜肽的疫苗
TWI485245B (zh) 2010-01-25 2015-05-21 Oncotherapy Science Inc 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗
US8673308B2 (en) * 2011-02-23 2014-03-18 Als Therapy Development Institute Targeting of CD8+ T-lymphocytes to treat neurodegenerative diseases
US10227610B2 (en) 2013-02-25 2019-03-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
KR102531016B1 (ko) 2014-11-21 2023-05-10 리제너론 파마슈티칼스 인코포레이티드 쌍 형성된 가이드 rna를 사용하는 표적화된 유전자 변형을 위한 방법 및 조성물
CN113831407B (zh) 2016-05-20 2024-06-11 瑞泽恩制药公司 用于使用多个引导rna来破坏免疫耐受性的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700637A (en) * 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US6251433B1 (en) 1996-08-13 2001-06-26 Chiron Corporation Polycationic polymers
US6197332B1 (en) 1997-08-13 2001-03-06 Chiron Corporation Lipid-conjugated polyamide compounds and related compositions and methods thereof
US6087485A (en) * 1998-01-21 2000-07-11 Axys Pharmaceuticals, Inc. Asthma related genes
WO1999065928A2 (en) 1998-06-19 1999-12-23 Genzyme Corporation Polynucleotide population isolated from non-metastatic and metastatic breast tumor tissues
ATE388226T1 (de) 1999-08-27 2008-03-15 Novartis Vaccines & Diagnostic Chimerische antisense-oligonukleotide und zelltransfektions-zusammensetzungen davon

Also Published As

Publication number Publication date
EP1292289B1 (de) 2008-03-05
WO2001091739A3 (en) 2003-01-16
DE60133104D1 (de) 2008-04-17
JP2003534786A (ja) 2003-11-25
US20050282766A1 (en) 2005-12-22
US20020049180A1 (en) 2002-04-25
PT1292289E (pt) 2008-04-23
WO2001091739A2 (en) 2001-12-06
EP1292289A2 (de) 2003-03-19
ES2299493T3 (es) 2008-06-01
CA2410516A1 (en) 2001-12-06
AU2001269726A1 (en) 2001-12-11
DE60133104T2 (de) 2009-03-12
US6974867B2 (en) 2005-12-13

Similar Documents

Publication Publication Date Title
MX2022000652A (es) Anticuerpos contra claudina 18 y metodos de tratamiento del cancer.
Fierro Jr et al. Dual-sgRNA CRISPR/Cas9 knockout of PD-L1 in human U87 glioblastoma tumor cells inhibits proliferation, invasion, and tumor-associated macrophage polarization
ATE387909T1 (de) Verfahren und zusammensetzungen zur behandlung von neoplastischen erkrankungen mittels chemotherapie und strahlungssensibilisatoren
Karlitepe et al. New approaches for cancer immunotherapy
SG170080A1 (en) Human monoclonal antibodies to o8e
ATE459648T1 (de) Fusionsprotein von antikörper l19 gegen fibronectin ed-b und interleukin 12
TW200513532A (en) VEGF traps and therapeutic uses thereof
ATE545699T1 (de) Modifizierte, rekombinante vacciniaviren und deren verwendungen
DE50106127D1 (de) Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites
DK0784683T3 (da) TIE-2-ligander, fremgangsmåder til dannelse af disse og anvendelser deraf
SG163554A1 (en) Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
ATE511503T1 (de) Aryl- und heteroarylharnstoff-chk1-inhibitoren zur verwendung als radiosensibilisatoren und chemosensibilisatoren
ATE517638T1 (de) Verfahren und zubereitungen zum verabreichen von therapeutischen und diagnostischen mitteln
Yin et al. Intranasal delivery of immunotherapeutic nanoformulations for treatment of glioma through in situ activation of immune response
WO2001093851A3 (en) Compositions and methods for treating neoplastic disease using inhibitors of laminin5beta3
NO993943D0 (no) Kombinert tumorsuppressorgenterapi og kjemoterapi ved behandling av neoplasmer
AU2003900481A0 (en) Synthetic modulators of cell migration and growth
ATE287722T1 (de) Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1
MX2025009229A (es) Molecula de union a antigeno triespecifica y uso de la misma
DE60109359D1 (de) Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten
EP1549760A4 (de) Sak: modulation der zellproliferation zur krebsbehandlung
MX2021008453A (es) Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos.
WO2004020979A3 (en) Methods of assaying for cell cycle modulators using components of the ubiquitin ligation cascade
Ruggeri Cancer 2021: new therapeutic approaches for the treatment of cancer—building on advances in cancer biology and the molecular genetics of cancer
WO2002006340A3 (en) Tetraspan protein and uses thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1292289

Country of ref document: EP

REN Ceased due to non-payment of the annual fee